Ultra-low-dose radioimmunotherapy improves prostate cancer treatment efficacy and safety
aState Key Laboratory of Vaccines for Infectious Diseases, Center for Molecular Imaging and Translational Medicine, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University, Xiamen 361102, China
bCancer Center, Dongguan Engineering Research Center for Innovative Boron Drugs and Novel Radioimmune Drugs, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Southern Medical University, Dongguan 523059, China
cGuangdong Engineering Research Center of Boron Neutron Therapy and Application in Malignant Tumors, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Southern Medical University, Dongguan 523059, China
收起